Policy paper proposes regulatory model for cognitive enhancement devices

April 24, 2014 by Carole Scott

Researchers from the Oxford Martin School, University of Oxford, are calling for the regulation of a new breed of devices designed to enhance the brain's performance. Cognitive enhancement devices (CEDs) offer the tantalising prospect of potentially making users' brains work faster, more effectively, and more creatively, and are now being marketed for gaming and education. But current European legislation subjects these devices to nothing more than basic product safety requirements, despite them directly modifying the electrical activity of the brain.

A new Oxford Martin policy paper proposes a regulatory model to help oversee this expanding industry. Authored by Hannah Maslen, Thomas Douglas, Roi Cohen Kadosh, Neil Levy and Julian Savulescu, Mind Machines: The Regulation of Cognitive Enhancement Devices provides a comprehensive overview of the types of devices available, assesses the regulatory weaknesses, and provides a practical pathway to designing a regulatory model for CEDs. In the EU, these products are not covered by the Medical Devices Directive because they are neither diagnostic nor therapeutic. So while the same kinds of devices are being trialled by scientists to treat conditions such as depression or Parkinson's disease, when the manufacturer makes no claim to therapeutic effect – either treatment or diagnosis – they are unregulated, with no system in place to guarantee their safety. With the market for enhancement technologies expanding and devices already crossing international borders, controlling which products are approved for sale is a global issue, potentially requiring international regulatory harmonisation.

Professor Julian Savulescu, Director of the Institute for Science and Ethics within the Oxford Martin School, comments: "CEDs open up a range of possibilities in increasing cognitive abilities, but are not risk-free. This paper's proposed regulatory model is directed at both policymakers and manufacturers, and seeks to ensure that consumers can be confident in their choices when purchasing a CED."

The commercial market for these devices is as yet unmeasured, with no sales figures available. The paper's lead author Dr Hannah Maslen, Research Fellow in Ethics on the Oxford Martin School Programme on Mind and Machine, says that this makes it the right time to act: "The market for these devices is still in its infancy, so now is the right time to address gaps in regulation to ensure their safety."

The paper's authors recommend that:

  • CEDs should be regulated within the EU Medical Devices Directive, as they possess similar mechanisms and risk profiles to some . This approach would allow for efficiency in legislation, with a precedent already set by the inclusion in the Directive of some non-medical (cosmetic) implantable and invasive devices.
  • High-risk devices must be prohibited; comprehensive and objective information from the manufacturers about mechanisms, safe use and risks and benefits must be provided for moderate-risk devices; and low-risk devices should be exempt from continued regulatory evaluation.
  • This model could be adopted in other jurisdictions across the world and, given the online market for these devices, international regulatory harmonisation is potentially required.
  • Criminal sanctions should be applied if CEDs intended for use on adults are used on children by individuals lacking adequate training.
  • CED manufacturers must exercise best practice in anticipation of regulatory oversight.

More information: The policy paper is available online: www.oxfordmartin.ox.ac.uk/downloads/briefings/Mind_Machines.pdf

Related Stories

Medical devices under scrutiny

May 18, 2011

‘When Suzanne Ludgate of the Medicines and Healthcare products Regulatory Agency (MHRA), the government regulator of medical devices in the UK, says she was "appalled at how many devices are brought to market with a ...

FDA issues final rule for device identification system

September 24, 2013

(HealthDay)—The U.S. Food and Drug Administration has released a final rule for the unique device identification system (UDI) that, when implemented, will improve patient safety by providing a consistent way to identify ...

FDA proposes accelerated medical device approval plan

April 23, 2014

(HealthDay)—The U.S. Food and Drug Administration has proposed a new program that would provide expedited access to high-risk medical devices intended for patients with serious conditions whose medical needs are not met ...

Recommended for you

Surprising similarity in fly and mouse motion vision

July 29, 2015

At first glance, the eyes of mammals and those of insects do not seem to have much in common. However, a comparison of the neural circuits for detecting motion shows surprising parallels between flies and mice. Scientists ...

Research grasps how the brain plans gripping motion

July 28, 2015

With the results of a new study, neuroscientists have a firmer grasp on the way the brain formulates commands for the hand to grip an object. The advance could lead to improvements in future brain-computer interfaces that ...

New research rethinks how we grab and hold onto objects

July 28, 2015

It's been a long day. You open your fridge and grab a nice, cold beer. A pretty simple task, right? Wrong. While you're debating between an IPA and a lager, your nervous system is calculating a complex problem: how hard to ...

It don't mean a thing if the brain ain't got that swing

July 27, 2015

Like Duke Ellington's 1931 jazz standard, the human brain improvises while its rhythm section keeps up a steady beat. But when it comes to taking on intellectually challenging tasks, groups of neurons tune in to one another ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

keiron_sparrowhawk
not rated yet Apr 25, 2014
I think this is a great initiative. At MyCognition we are developing video games to assess and train cognition. I think we are ahead of the curve in that we are undertaking trials and clinical studies of our products to provide the evidence and to meet EMA levels of approval. Ultimately we want FDA and EMA approval so that doctors can prescribe them. Please visit www.mycognition.com
Thank you.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.